Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.…
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Misses Revenue Estimates
Sol-Gel Technologies (NASDAQ: SLGL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 28 employees.
The shares were at 55.17 USD on 20 November 2026, up 73.0% over 52 weeks. Its 52-week range is 28.81 USD to 97.97 USD: the price is 43.7% below the high and 91.5% above the low.
Its market capitalisation is 180.63M USD.
Sol-Gel Technologies reports return on equity of -26.9% and revenue down 89.8% year over year.
It holds more cash than debt, a net cash position of 43.61M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 155.50 USD is 181.9% above the current price. The next earnings report is expected on 18 March 2027.